Clinical trial
Trastuzumab in Treating Patients With Prostate Cancer
NCT00003740 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003740 |
|---|---|
| Title | Trastuzumab in Treating Patients With Prostate Cancer |
| Official title | Phase II Study of Herceptin (Recombinant Humanized Anti-p185HER2 Monoclonal Antibody) for the Treatment of Androgen Independent Prostate Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | trastuzumab |
| Start date | Oct 1, 1998 |
| Primary completion | Sep 1, 2002 |
| Completion | Sep 1, 2002 |
| First posted | Jun 3, 2004 |
| Last update posted | Jun 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: